About Vensana Capital
Vensana Capital is a venture capital firm founded in 2019. It is primarily based out of Minneapolis, United States. As of Jul 2026, Vensana Capital is an active investor, having invested in 44 companies, with 2 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Series A round of TYBR Health Overall, Vensana Capital portfolio has seen 3 IPOs and 20 acquisitions including key companies like Senseonics, CVRx and Inari Medical. A lot of funds co-invest with Vensana Capital, with names like Hatteras Venture Partners sharing a substantial percentage of its portfolio. Vensana Capital has team of 28 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 4 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Vensana Capital's List of Top Investments
Vensana Capital has a portfolio of 44 companies. Their most notable investments are in Volta Medical and Okami Medical.Their portfolio spans across United States, France and Ireland. They have invested in Life Sciences, HealthTech, Enterprise Applications and 3 other sectors, across stages such as Series B, Series A and 4 more. Here is the list of top investments by Vensana Capital:1. Senseonics
Provider of implantable systems for continuous glucose monitoring. It designs, develops and commercializes glucose monitoring systems to be used directly by people. Their continuous glucose monitoring (CGM) system is an implantable system that has been designed to continually measure glucose levels in people with diabetes for a period of up to 90 days. Their CGM system includes a Sensor, Transmitter, and Mobile Medical Application. The miniaturized Sensor is designed to be implanted into the subcutaneous space of the upper arm and requires no battery or wires for the Sensor to communicate with the Transmitter. It has a connected app which provides the patient with a report of their glucose level.
Key facts about Senseonics
- Founded Year: 1996
- Location: Germantown (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $165M
- Employee Count: 288 as on Aug 31, 2026
- Investors: Greenspring Associates, Vensana Capital and 9 Others
- Latest Funding Round: Post IPO, May 20, 2025, $*****
- Highlight: Public
2. CVRx
CVRx is a developer of implantable technology for hypertension and heart failure. The product Barostim neo is implanted under the skin, similar to a pacemaker. It then sends signals to the body's cardiovascular regulators to improve cardiac and vascular function by restoring sympathovagal balance through activation of the afferent and efferent pathways of the autonomic nervous system. The product is CE marked and approved for sale in Europe for both indications.
Key facts about CVRx
- Founded Year: 2001
- Location: Minneapolis (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $394M
- Employee Count: 262 as on Aug 31, 2026
- Investors: Gilde Healthcare, Piper Jaffray and 21 Others
- Latest Funding Round: Series F, Jul 07, 2020, $*****
- Highlight: Public
Pioneering innovative medical devices for venous thromboembolism treatment. The company is dedicated to elevating the standard of care for venous thromboembolism (VTE) patients through innovative products and clinical evidence. They specialize in mechanical thrombectomy systems designed for the treatment of pulmonary embolism (PE), deep vein thrombosis (DVT), and in-stent thrombosis. Their solutions include devices for venous access and blood return systems, aiming to maximize thrombus removal and restore access. They offer educational programs, reimbursement resources, and support for healthcare providers and patients. The company focuses on research and development to advance VTE treatment and improve patient outcomes.
Key facts about Inari Medical
- Founded Year: 2011
- Location: Irvine (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2023
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $51.9M
- Employee Count: 607 as on Aug 31, 2026
- Investors: HTIF, Gilde Healthcare and 5 Others
- Latest Funding Round: Series C, Mar 29, 2018, $*****
- Highlight: Acquired
4. Cleerly
Provider of an AI-driven platform for coronary artery disease assessment. The platform quantifies atherosclerosis by measuring plaque volume, composition, length, and location. It evaluates stenosis severity and determines the likely presence or absence of ischemia. The software aims to reduce the need for additional testing and enhance diagnostic confidence.
Key facts about Cleerly
- Founded Year: 2016
- Location: Denver (United States)
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $578M
- Employee Count: 399 as on Sep 30, 2026
- Investors: T. Rowe Price, Fidelity Investments and 20 Others
- Latest Funding Round: Series C, Nov 19, 2024, $*****
- Highlight: Editors' Pick
5. Apella
Developer of surgical systems for the operating room. The products of the company include sensors for operating rooms that harness artificial intelligence approaches to collect and analyze new data about surgery. It has applications targeted at improving hospital operations, surgical quality, staff training, and real-time decision-making.
Key facts about Apella
- Founded Year: 2021
- Location: San Francisco (United States)
- Stage: Series B
- Total Funding till date: $101M
- Employee Count: 131 as on Aug 31, 2026
- Investors: K2 HealthVentures, Vensana Capital and 8 Others
- Latest Funding Round: Series B, Jan 08, 2026, $*****
- Highlight: Editors' Pick
Vensana Capital's Year-on-Year Investment Trends
Vensana Capital has invested in 44 companies over the last 7 years, with an average of 3 new investments annually in the last 5 years. In 2025, it made 5 investments, while as of Jul 2026, it has made 3 investments in this year. Its most recent first time investment was in TYBR Health and most recent follow-on round was in Apella.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 1 | 3 |
2025 | 2 | 3 | 5 |
2024 | 3 | 1 | 4 |
2023 | 5 | 1 | 6 |
2022 | 2 | 2 | 4 |
2021 | 4 | 0 | 4 |
2020 | 2 | 0 | 2 |
2019 | 2 | 0 | 2 |
Vensana Capital's Investments by Stage
Vensana Capital has made 8 investments in Series B stage with an average round size of $36.5M, 7 investments in Series A stage with an average round size of $26.8M and 3 investments in Series C stage with an average round size of $78.5M.Stage of entry | No. of Investments |
|---|---|
Series B | 8 |
Series A | 7 |
Series C | 3 |
Series F | 2 |
Series D | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Vensana Capital's Investments by Sector
Vensana Capital has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, HealthTech, Healthcare and Vertical SaaS. Notably, it has invested in 41 Tech companies, 40 Enterprise (B2B) companies, 16 Software companies and at least 15 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 14 |
Enterprise Applications | 5 |
HealthTech | 5 |
Healthcare | 2 |
Vertical SaaS | 2 |
Others | 3 |
Note: We have considered here, only first round of investments
Vensana Capital's Investments by Geography
Vensana Capital has made most investments in United States (21), followed by France where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 21 |
France | 1 |
Note: We have considered here, only first round of investments
Vensana Capital's recent investments
Vensana Capital has made 3 investments in 2026 so far. TYBR Health and Apella are the latest among them.Here are the most recent investments by Vensana Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 09, 2026 | United States | Series A | 2900 | ||
Jan 08, 2026 | United States | Series B | 2095 | [+7] | |
Jan 06, 2026 | United States | Series A | 2653 | [+3] | |
Nov 18, 2025 | United States | Series F | 6658 | [+1] | |
Aug 12, 2025 | United States | Series A | 9899 |
IPOs and Publicly Listed companies in Vensana Capital's Portfolio
3 of Vensana Capital's portfolio companies have become public. SpyGlass got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2026 at marketcap of $511M and CVRx got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $126M.Here are Vensana Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 06, 2026 | Jul 10, 2023 | Series C | 6201 | |
Jun 30, 2021 | Jul 07, 2020 | Series F | 3387 | |
Feb 11, 2016 | - | - | 5947 |
Acquired companies in Vensana Capital's Portfolio
20 companies from Vensana Capital's portfolio have been acquired. The most recent acquisition was Moxe Health in Mar 2026 by BV Investment Partners for $*****.Here are Vensana Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 10, 2026 | Jun 01, 2022 | Series B | 3784 | |
Jan 06, 2025 | - | - | 3306 | |
Jun 03, 2024 | May 24, 2023 | Series B | 6034 | |
Sep 19, 2023 | Oct 22, 2020 | Series F | 7934 | |
Dec 23, 2021 | Feb 10, 2021 | Series C | 8872 |
Team profile of Vensana Capital
Vensana Capital has a team of 28 members including 5 Partners and 1 Venture Partner located in United States. Vensana Capital's team sits on the board of 1 company.Here is a list of top team members in Vensana Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | - | |
Partner | United States | |||
Partner | Minneapolis | - | ||
Partner | Minneapolis | - | ||
Partner | Boston | - | ||
Venture Partner | United States | - |
Co-investors of Vensana Capital
Over the past 7 years, 127 investors have co-invested in Vensana Capital's portfolio companies. This includes funds and angels.
- Invested before Vensana Capital: New Enterprise Associates, Gilde Healthcare and 52 others have invested in rounds before Vensana Capital. There are 5 companies where New Enterprise Associates has invested before Vensana Capital and 2 companies where Gilde Healthcare has invested before Vensana Capital.
- Top Co-investors of Vensana Capital: 47 investors entered a company along with Vensana Capital. These include investors like Hatteras Venture Partners (2 companies).
- Invested after Vensana Capital: A total of 26 investors have invested in Vensana Capital's portfolio after their investments. Top Investors include Gilde Healthcare (3 companies), T. Rowe Price (1 company) and Fidelity Investments (1 company).
Recent News related to Vensana Capital
•
TYBR Health Secures $30 Million Series A FinancingPR Newswire•Jul 21, 2026•Vensana Capital, Mutual Capital Partners, TYBR Health
•
Ventaris Surgical Raises $30M in Series A FundingFinSMEs•Jan 12, 2026•Atypical, Vensana Capital, Longitude Capital, Neotribe and 3 others
•
Apella Secures $80M to Scale Ambient Video Intelligence Across Surgical SuiteHIT Consultant•Jan 08, 2026•Apella, Vensana Capital, K2 HealthVentures, Houston Methodist and 5 others
•
Okami Medical Secures $45 Million Financing and Appoints New CEO to Spearhead GrowthPR Newswire•Nov 19, 2025•Okami Medical, Evtoday, Vensana Capital, Gilde Healthcare and 1 other
•
Relievant Medsystems Closes $50 Million Series G FinancingG-MedTech•Nov 06, 2025•Vensana Capital, Ally Bridge Group, Lightstone Ventures
•
Vensana Capital Launches Vensana Innovation and Adds Thomas Tu, MD as Venture PartnerBusiness Wire•Oct 07, 2025•Vensana Capital
•
Luna Diabetes Secures $23.6M Series A to Advance Automated Insulin Delivery for Pen Usersbignewsnetwork.com•Aug 18, 2025•Ascensia, Vensana Capital
•
Luna Health secures $23.6M in Series A funding for insulin patch pumpThe Globe and Mail•Aug 18, 2025•Diabetes Venture Fund, Ascensia, Vensana Capital, Winklevoss Capital
•
Luna Diabetes Raises Series A Financing to Advance its Automated Insulin Delivery Solution For Insulin Pen UsersAccess Newswire•Aug 18, 2025•Luna Diabetes, Diabetes Venture Fund, Ascensia, Vensana Capital and 1 other
•
Rampart IC Secures $21.6M Series B Funding for Radiation Safety SolutionsHMP Global Learning Network•Apr 25, 2025•Rampart, Vensana Capital
